FDA Brief

Warning letters Drugs

FDA warning letter to

Champaklal Maganlal Homeo Pharmacy Private Limited

High riskIssued Apr 10, 2023Posted Apr 11, 2023Center for Drug Evaluation and Research | CDER

Champaklal Maganlal Homeo Pharmacy failed to test each glycerin lot for identity, including DEG/EG, in OTC and homeopathic drugs.

What happened

FDA reviewed records the company submitted after FDA's November 15, 2022 request under section 704(a)(4) of the FD&C Act. FDA found the company did not test each shipment of each glycerin lot for identity with the USP identification test that limits diethylene glycol (DEG) and ethylene glycol (EG), even though some formulations contain high percentages of glycerin. The company also tested retain samples of some finished batches shipped to or distributed in the U.S. using a 2018 Indian Pharmacopeia method but did not show the method was suitable for DEG/EG in finished drug product, did not test every lot, and did not provide supporting analytical data.

What FDA found

  1. The firm did not perform at least one identity test on each incoming component lot; for glycerin, it did not test each shipment of each lot with the USP identification test that sets limits for DEG and EG.

    21 CFR 211.84(d)(1)
  2. The firm tested retain samples of only some finished batches shipped to or distributed in the U.S. for DEG and EG using a 2018 Indian Pharmacopeia glycerin method, but did not show that method was suitable for the finished drug product.

  3. The firm did not test every lot of drug product shipped to or distributed and did not provide evidence such as quantitative worksheets and chromatograms to support the analytical testing results.

What FDA wants

FDA tells the company to respond in writing within 15 working days and, within 30 calendar days, provide DEG/EG test results for all glycerin lots, a risk assessment, customer notifications and recalls if needed, a supplier qualification/material system review, component testing plans, specifications, and a laboratory system assessment.

Who should pay attention

  • brands that buy finished OTC or homeopathic drugs from this manufacturer
  • drugmakers that use glycerin in their products
  • U.S. importers of glycerin-containing drug products

This is a summary. Read the original letter on fda.gov.

Champaklal Maganlal Homeo Pharmacy Private Limited's FDA history

  1. Champaklal Maganlal Homeo Pharmacy Private Limited

    FDA says Champaklal Maganlal Homeo Pharmacy's Bebelyn diarrhea and colic products are unapproved new drugs for infants.

    High risk

Full company page

Similar letters to other companies

  1. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  2. Laboratoire Druide Inc.

    FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.

    High risk
  3. Eurosirel S.P.A

    FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.

    High risk
  4. Seoul Cosmetics Co., Ltd.

    FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

    High risk